KRAS Mutation, Not G12C: — What Treatment Options Do You Have?

The G12C change creates a unique molecular pocket that forms only when the KRAS protein is in its inactive state. Inhibitor drugs bind to that pocket and hold the protein switched off. G12D, G12V, and other variants do not have this pocket — they tend to stay active and are much harder to block with a small molecule. Research to solve this is intensive, and several G12D inhibitors have entered early-phase trials, but none has yet completed the regulatory review needed for approval. The difference is molecular structure, not a gap in scientific effort.

No. Sotorasib and adagrasib are covalent inhibitors designed to bind specifically to the cysteine created by the G12C change. G12D, G12V, and other variants do not have that cysteine, so the drugs have nothing to attach to. Using a G12C inhibitor for a different KRAS variant would not produce any benefit, and it would still expose you to the same side-effect risks. If you have seen reports about these drugs and wondered whether they apply to your result, your oncologist can confirm it directly from your molecular report.

KRAS status alone does not determine immunotherapy eligibility. Eligibility is based on PD-L1 expression and microsatellite instability, both tested on tumour tissue, and those results are independent of which KRAS variant you carry. ASCO and ESMO guidance uses those markers — not KRAS — as the primary criteria for immunotherapy decisions. The practical step is to confirm that PD-L1 and MSI testing has been done, because those are the results your oncologist needs to advise you on immunotherapy.

Trials are opening progressively in India as G12D and pan-KRAS inhibitor studies expand internationally. Some global trials include recruiting centres in Indian cities. Eligibility criteria differ considerably — some require a specific variant, a specific cancer type, or a defined prior-treatment history — so there is no general answer about what is available for you specifically. Your oncologist is best placed to check what is currently open. The Clinical Trials Registry of India lists studies with Indian sites and is publicly searchable. Ask explicitly at your next appointment.

Many standard mutation panels used in India report KRAS mutation without identifying the specific variant. This is worth addressing, because clinical trial eligibility for most non-G12C studies requires knowing the exact variant. Ask your oncologist to retrieve the full result from the original laboratory report — the variant is often in the raw data even when the clinical summary does not name it. If the original test did not capture it, next-generation sequencing on stored tumour tissue can usually identify it.

The relationship between KRAS mutation and cancer behaviour depends on the variant, the cancer type, and what other genetic changes are present alongside it. It is not a single, uniform answer. What is consistent across NCCN, ASCO, and ESMO guidance is that KRAS status is used to inform treatment planning — it does not place a patient outside the available options. Your oncologist can explain what your specific variant means for your diagnosis, which is more useful than a general statement about KRAS.